Upcoming Events

Past studies

  • A double-blind, randomized, placebo-controlled phase I study to evaluate and compare the safety and immunogenicity of HIV-1 clade A DNA vaccine given once or twice followed by 2 doses of HIV-1 clade A MVA vaccine in healthy adult Ugandan volunteers who are not infected with HIV.
  • A cross sectional, observational study to establish clinical laboratory reference ranges in adults at multiple sites in Africa.
  • A phase 2, randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of tgAAC09, an HIV vaccine containing clade C gag-PR-?RT DNA in an Adeno-Associated Virus (AAV) capsid, administered twice, at three dosage levels and two dosing intervals.
  • A study to compare DNA microarray immune response profiles in healthy Ugandan adults against profiles in south and north American populations using the yellow fever vaccine